Certain patientssuch as those with specific types of endocrine cancersshould avoid GLP1s, he explained, and there are clear guidelines for who may benefit most, including people with diabetes, obesity or other chronic conditions that contribute to long-term weight gain
**Who should consider it:** Patients who have plateaued on Semaglutide or Tirzepatide, those seeking the highest available efficacy, early adopters comfortable with a medication still in trials, and always under close medical supervision
(Lausanne) 9 , 813204 (2022)
In general, the beverage industry has been treating the expansion of GLP-1 use with measured caution
The AI In 1998, the Food and Nutrition Board (FNB) of the Institute of Medicine (now the National Academy of Medicine) established a dietary reference intake (DRI) for choline (32)
Hansen, Z